Elif Hindié

Dr. Elif Hindié

Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Elif HindiéElif Hindié
Elif Hindié
PZPaolo Zanotti-Fregonara
Paolo Zanotti-Fregonara
MQMichele A. Quinto
Michele A. Quinto
CMClément Morgat
Clément Morgat
CCChristophe Champion
Christophe Champion
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of 90Y, 177Lu, 111In, and 161Tb at irradiating micrometastases. 90Y and 177Lu are widely used β−-emitting radionuclides. 161Tb is a medium-energy β− radionuclide that is similar to 177Lu but emits a higher percentage of conversion and Auger electrons. 111In emits γ-photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of 90Y, 177Lu, 111In, or 161Tb in spheres with diameters ranging from 10 mm to 10 μm. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per μm3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by 90Y, 177Lu, 111In, and 161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for 90Y. In a 100-μm metastasis, the dose delivered by 90Y was only 1.36 Gy, compared with 24.5 Gy for 177Lu, 38.9 Gy for 111In, and 44.5 Gy for 161Tb. In cell-sized spheres, the dose delivered by 111In and 161Tb was higher than that of 177Lu. For instance, in a 10-μm cell, 177Lu delivered 3.92 Gy, compared with 22.8 Gy for 111In and 14.1 Gy for 161Tb. Conclusion: 177Lu, 111In, and 161Tb might be more appropriate than 90Y for treating minimal residual disease. 161Tb is a promising radionuclide because it combines the advantages of a medium-energy β− emission with those of Auger electrons and emits fewer photons than 111In.

19 May 2020 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
MAMario E. Alcocer-Ávila
Mario E. Alcocer-Ávila
AFAymeric Ferreira
Aymeric Ferreira
MQMichele A. Quinto
Michele A. Quinto
CMClément Morgat
Clément Morgat
Elif HindiéElif Hindié
Elif Hindié
CCChristophe Champion
Christophe Champion
Background: Targeted radionuclide therapy (TRT) is gaining importance. For TRT to be also used as adjuvant therapy or for treating minimal residual disease, there is a need to increase the radiation dose to small tumours. The aim of this in silico study was to compare the performances of 161Tb (a medium-energy β− emitter with additional Auger and conversion electron emissions) and 177Lu for irradiating single tumour cells and micrometastases, with various distributions of the radionuclide. Methods: We used the Monte Carlo track-structure (MCTS) code CELLDOSE to compute the radiation doses delivered by 161Tb and 177Lu to single cells (14 μm cell diameter with 10 μm nucleus diameter) and to a tumour cluster consisting of a central cell surrounded by two layers of cells (18 neighbours). We focused the analysis on the absorbed dose to the nucleus of the single tumoral cell and to the nuclei of the cells in the cluster. For both radionuclides, the simulations were run assuming that 1 MeV was released per μm3 (1436 MeV/cell). We considered various distributions of the radionuclides: either at the cell surface, intracytoplasmic or intranuclear. Results: For the single cell, the dose to the nucleus was substantially higher with 161Tb compared to 177Lu, regardless of the radionuclide distribution: 5.0 Gy vs. 1.9 Gy in the case of cell surface distribution; 8.3 Gy vs. 3.0 Gy for intracytoplasmic distribution; and 38.6 Gy vs. 10.7 Gy for intranuclear location. With the addition of the neighbouring cells, the radiation doses increased, but remained consistently higher for 161Tb compared to 177Lu. For example, the dose to the nucleus of the central cell of the cluster was 15.1 Gy for 161Tb and 7.2 Gy for 177Lu in the case of cell surface distribution of the radionuclide, 17.9 Gy for 161Tb and 8.3 Gy for 177Lu for intracytoplasmic distribution and 47.8 Gy for 161Tb and 15.7 Gy for 177Lu in the case of intranuclear location. Conclusion: 161Tb should be a better candidate than 177Lu for irradiating single tumour cells and micrometastases, regardless of the radionuclide distribution.

4 September 2014 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
CMClément Morgat
Clément Morgat
AMAnil Kumar Mishra
Anil Kumar Mishra
RVRaunak Varshney
Raunak Varshney
MAMichèle Allard
Michèle Allard
PFPhilippe Fernandez
Philippe Fernandez
Elif HindiéElif Hindié
Elif Hindié
Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.

1 January 2016 in Theranostics
Verified
Journal Article
Open access
CCChristophe Champion
Christophe Champion
MQMichele A. Quinto
Michele A. Quinto
CMClément Morgat
Clément Morgat
PZPaolo Zanotti-Fregonara
Paolo Zanotti-Fregonara
Elif HindiéElif Hindié
Elif Hindié
PURPOSE: Radionuclide therapy is increasingly seen as a promising option to target minimal residual disease. Copper-67, scandium-47 and terbium-161 have a medium-energy β- emission which is similar to that of lutetium-177, but offer the advantage of having diagnostic partner isotopes suitable for pretreatment imaging. The aim of this study was to compare the efficacy of 67Cu, 47Sc and 161Tb to irradiate small tumors.

17 January 2013 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MHMathieu Hatt
Mathieu Hatt
David GROHEUXDavid GROHEUX
David GROHEUX
AMAntoine Martineau
Antoine Martineau
MEMarc Espié
Marc Espié
Elif HindiéElif Hindié
Elif Hindié
CRCatherine Cheze-Le Rest
Catherine Cheze-Le Rest
The goal of this study was to determine the best predictive factor among image-derived parameters extracted from sequential 18F-FDG PET scans for early tumor response prediction after 2 cycles of neoadjuvant chemotherapy in breast cancer. Methods: 51 breast cancer patients were included. Responder and nonresponder status was determined by histopathologic examination according to the tumor and node Sataloff scale. PET indices (maximum and mean standardized uptake value [SUV], metabolically active tumor volume, and total lesion glycolysis [TLG]), at baseline and their variation (Δ) after 2 cycles of neoadjuvant chemotherapy were extracted from the PET images. Their predictive value was investigated using Mann–Whitney U tests and receiver-operating-characteristic analysis. Subgroup analysis was also performed by considering estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative, triple-negative, and HER2-positive tumors separately. The impact of partial-volume correction was also investigated using an iterative deconvolution algorithm. Results: There were 24 pathologic nonresponders and 27 responders. None of the baseline PET parameters was correlated with response. After 2 neoadjuvant chemotherapy cycles, the reduction of each parameter was significantly associated with response, the best prediction of response being obtained with ΔTLG (96% sensitivity, 92% specificity, and 94% accuracy), which had a significantly higher area under the curve (0.91 vs. 0.82, P = 0.01) than did ΔSUVmax (63% sensitivity, 92% specificity, and 77% accuracy). Subgroup analysis confirmed a significantly higher accuracy for ΔTLG than ΔSUV for ER-positive/HER-negative but not for triple-negative and HER2-positive tumors. Partial-volume correction had no impact on the predictive value of any of the PET image–derived parameters despite significant changes in their absolute values. Conclusion: Our results suggest that the reduction after 2 neoadjuvant chemotherapy cycles of the metabolically active volume of primary tumor measurements such as ΔTLG predicts histopathologic tumor response with higher accuracy than does ΔSUV measurements, especially for ER-positive/HER2-negative breast cancer. These results should be confirmed in a larger group of patients as they may potentially increase the clinical value and efficiency of 18F-FDG PET for early prediction of response to neoadjuvant chemotherapy.

9 April 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Elif HindiéElif Hindié
Elif Hindié
PZPaolo Zanotti-Fregonara
Paolo Zanotti-Fregonara
ATAntoine Tabarin
Antoine Tabarin
DRDomenico Rubello
Domenico Rubello
IMIsabelle Morelec
Isabelle Morelec
DTDavid Taïeb
David Taïeb
Primary hyperparathyroidism is a frequent and potentially debilitating endocrine disorder for which surgery is the only curative treatment. The modalities of parathyroid surgery have changed over the last 2 decades, as conventional bilateral neck exploration is no longer the only surgical approach. Parathyroid scintigraphy plays a major role in defining the surgical strategy, given its ability to orient a targeted (focused) parathyroidectomy and to recognize ectopic locations or multiglandular disease. This review, which represents a collaborative effort between nuclear physicians, endocrinologists, and endocrine surgeons, emphasizes the importance of performing imaging before any surgery for primary hyperparathyroidism, even in the case of conventional bilateral neck exploration. We discuss the advantages and drawbacks of targeted parathyroidectomy and the performance of various scintigraphic protocols to guide limited surgery. We also discuss the optimal strategy to localize the offending gland before reoperation for persistent or recurrent hyperparathyroidism. Finally, we describe the potential applications of novel PET tracers, with special emphasis on 18F-fluorocholine.